Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study
- 280 Downloads
Chest pain is one of the most common reasons for presentation to the Emergency Department and the ability to rapidly and correctly diagnose the minority of patients who have a myocardial infarction is of critical importance. We assessed the diagnostic performance of a multimarker strategy using heart-type fatty acid binding protein (H-FABP) in combination with a contemporary sensitive troponin (cTn) assay. We measured H-FABP (Randox) and a sensitive cTn (TnI-Ultra, Siemens) at baseline in 343 patients with chest pain enrolled in the prospective BWH-TIMI ED chest pain study. Final presenting diagnosis was adjudicated using all diagnostic data, including the local cTnI results, but reviewers were blinded to H-FABP and the sensitive cTn assays. The diagnostic accuracy of H-FABP and local cTn together (AUC 0.962) was superior to local cTn alone (AUC 0.910, p = 0.0009) with an especially marked improvement in early presenters (AUC 0.983 vs. 0.840, p = 0.0098). In contrast, when combined with the sensitive cTn assay, there was no significant difference in the AUC with H-FABP as compared with the sensitive cTn alone, either in the overall cohort (AUC 0.963 vs. 0.956, p = 0.23) or in early presenters (AUC 0.999 for both). In early presenters, the addition of H-FABP resulted in a NPV of 100 % when combined with either the local or sensitive cTn assay. In our study, the addition of H-FABP significantly enhanced the sensitivity and accuracy of diagnosis as compared to a prior-generation troponin assay alone, especially in patients who presented early. H-FABP but did improve overall diagnostic accuracy when added to a current-generation sensitive troponin assay; however, their combination offered the best NPV in early presenters. Further studies are needed to determine the utility a very rapid “rule out” of MI with a single blood draw of troponin and H-FABP at presentation.
KeywordsChest pain Emergency department H-FABP Myocardial infarction Acute coronary syndromes
The TIMI Study Group has received research Grant support from Abbott, Amgen, AstraZeneca, Beckman Coulter, BG Medicine, BRAHMS, Bristol-Myers Squibb, Buhlmann, Critical Diagnostics, CV Therapeutics, Daiichi Sankyo Co Ltd, Eli Lilly and Co, GlaxoSmithKline, Merck and Co, Nanosphere, Novartis Pharmaceuticals, Ortho-Clinical Diagnostics, Pfizer, Randox, Roche Diagnostics, Sanofi-Aventis, Siemens, and Singulex.
Conflict of interest
Dr. Ruff is an investigator and receives salary support from the TIMI Study Group. He has received remuneration for consulting from Alere, Beckman Coulter, Daiichi Sankyo, Boerhinger-Ingelheim. Dr. Bonaca is an investigator and receives salary support from the TIMI Study Group. Dr. Kosowsky, Mr. Conrad, Mrs. Murphy none to report. Dr. Jarolim has received research grant support from Beckman-Coulter, Amgen, BRAHMS, Daiichi Sankyo, Merck & Co., Abbott, Ortho-Clinical Diagnostics, Roche, and Siemens. Has received honoraria from Ortho-Clinical Diagnostics and served as a consultant to T2 Biosystems and Quanterix. Dr. Donahoe none to report. Dr. O’Donoghue is an investigator and receives salary support from the TIMI Study Group. She has received remuneration for consulting from Aegerion. Dr. Morrow is an investigator and receives salary from the TIMI Study Group. He has received remuneration for consulting from Beckman-Coulter, Boehringher Ingelheim, Critical Diagnostics, Genentech, Gilead, Instrumentation Laboratory, Johnson & Johnson, Merck, Roche Diagnostics, and Servier.
- 3.Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr., 2004 Writing Committee Members, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. (2008) 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with st-elevation myocardial infarction: a report of the American college of cardiology/american heart association task force on practice guidelines: developed in collaboration with the canadian cardiovascular society endorsed by the American academy of family physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation 117: 296–329Google Scholar
- 4.Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, E. CD Jr., Chavey WE, 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, C. SS Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons endorsed by the American association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine. J Am Coll Cardiol 50: e1–e157Google Scholar
- 9.Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH, Cannon CP, Francis G, Morrow DA, Ravkilde J, Storrow AB, Tang W, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Panteghini M, Tate J (2007) National academy of clinical biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem 53:547–551PubMedCrossRefGoogle Scholar
- 10.Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Frohlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Munzel TF, Blankenberg S (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361:868–877PubMedCrossRefGoogle Scholar
- 11.Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361:858–867PubMedCrossRefGoogle Scholar
- 17.Ishii J, Wang JH, Naruse H, Taga S, Kinoshita M, Kurokawa H, Iwase M, Kondo T, Nomura M, Nagamura Y, Watanabe Y, Hishida H, Tanaka T, Kawamura K (1997) Serum concentrations of myoglobin vs human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem 43:1372–1378PubMedGoogle Scholar
- 18.Okamoto F, Sohmiya K, Ohkaru Y, Kawamura K, Asayama K, Kimura H, Nishimura S, Ishii H, Sunahara N, Tanaka T (2000) Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med 38:231–238PubMedCrossRefGoogle Scholar
- 19.Seino Y, Ogata K, Takano T, Ishii J, Hishida H, Morita H, Takeshita H, Takagi Y, Sugiyama H, Tanaka T, Kitaura Y (2003) Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobin tests. Am J Med 115:185–190PubMedCrossRefGoogle Scholar
- 23.Kagawa Y, Toyofuku M, Masaoka Y, Muraoka Y, Okimoto T, Otsuka M, Tamekiyo H, Mito S, Kawase T, Yamane K, Senoo A, Amioka M, Shiode N, Hayashi Y (2011) Comparison of heart-type fatty acid binding protein and sensitive troponin for the diagnosis of early acute myocardial infarction. Int J Cardiol (in print)Google Scholar
- 24.Lindsell CJ, Anantharaman V, Diercks D, Han JH, Hoekstra JW, Hollander JE, Kirk JD, Lim SH, Peacock WF, Tiffany B, Wilke EK, Gibler WB, Pollack CV Jr. (2006) EMCREG-international i*trACS investigators. The internet tracking registry of acute coronary syndromes (i*trACS): a multicenter registry of patients with suspicion of acute coronary syndromes reported using the standardized reporting guidelines for emergency department chest pain studies. Ann Emerg Med 48: 666–77, 677. e1–9Google Scholar
- 27.Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, Bassetti S, Steuer S, Winkler K, Peter F, Meissner J, Haaf P, Potocki M, Drexler B, Osswald S, Mueller C (2011) Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation 124:136–145PubMedCrossRefGoogle Scholar
- 29.Viswanathan K, Kilcullen N, Morrell C, Thistlethwaite SJ, Sivananthan MU, Hassan TB, Barth JH, Hall AS (2010) Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol 55:2590–2598PubMedCrossRefGoogle Scholar